Top

Published in:

01-12-2020 | Fertility | Review

Fertility preservation in BRCA mutation carriers—efficacy and safety issues: a review

Authors: Xiaofu Zhang, Jingxin Niu, Tuanjie Che, Yibei Zhu, Hongtao Zhang, Jing Qu

Published in: Reproductive Biology and Endocrinology | Issue 1/2020

Abstract

BRCA mutation carriers face various situations that influence their fertility potential. There is still a lack of guideline or expert consensus on Fertility Preservation (FP) in BRCA mutation carriers and the necessity and safety of FP in BRCA mutation carriers is still in dispute. This review aims to focus on the population of BRCA mutation carriers by analyzing the existing FP strategies, comprehensively comparing the pros and cons of each strategy and its applicability.

FP is a suggestion for BRCA mutation carriers with birth planning. Different FP strategies have different characteristics. Considering the particularity of BRCA mutation carriers, multiple factors need to be carefully considered. This review focuses on the applicability of each FP method for carriers under various circumstances. Available FP strategies including oocyte cryopreservation, ovarian tissue cryopreservation, preimplantation genetic diagnosis, and egg/embryo donation are analyzed by comparing existing methods comprehensively. In the attempt to provide an up-to-date decision-making guidance. Conditions taking into consideration were the carrier’s age, the risk of breast and ovarian metastasis, plans for oncotherapy, FP outcome, time available for FP intervention and accessibility.

Overall, FP is necessary and safe for BRCA mutation carriers. Among all available FP methods, oocyte cryopreservation is the most reliable procedure; ovarian tissue cryopreservation is the only way for preserving both fertility and endocrine function, recommended for pre-pubertal carriers and when time is limited for oocyte stimulation. A clear framework provides frontline clinical practitioners a new thought and eventually benefit thousands of BRCA mutation carriers.

Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science (New York, NY). 1990;250(4988):1684–9.CrossRef

Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science (New York, NY). 1994;265(5181):2088–90. https://doi.org/10.1126/science.8091231.CrossRef

Dasika GK, Lin S-CJ, Zhao S, Sung P, Tomkinson A, Lee EYHP. DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene. 1999;18(55):7883–99. https://doi.org/10.1038/sj.onc.1203283.CrossRefPubMed

Collins N, McManus R, Wooster R, Mangion J, Seal S, Lakhani SR, et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene. 1995;10(8):1673–5.PubMed

Smith SA, Easton DF, Evans DG, Ponder BA. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet. 1992;2(2):128–31.CrossRefPubMed

Esteller M, Fraga MF, Guo M, Garcia-Foncillas J, Hedenfalk I, Godwin AK, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet. 2001;10(26):3001–7.CrossRefPubMed

Moschetta M, George A, Kaye SB, Banerjee S. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann Oncol. 2016;27(8):1449–55.CrossRefPubMed

Weitzel JN, Lagos VI, Cullinane CA, Gambol PJ, Culver JO, Blazer KR, et al. Limited Family Structure and BRCA Gene Mutation Status in Single Cases of Breast Cancer. JAMA. 2007;297(23):2587–95. https://doi.org/10.1001/jama.297.23.2587.CrossRefPubMed

Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer. 2004;4(10):814–9. https://doi.org/10.1038/nrc1457.CrossRefPubMed

10.

Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Roos-Blom M-J, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersRisks of Breast, Ovarian, and Contralateral Breast Cancer Among BRCA Mutation CarriersRisks of Breast, Ovarian, and Contralateral Breast Cancer Among BRCA Mutation Carriers. JAMA. 2017;317(23):2402–16. https://doi.org/10.1001/jama.2017.7112.CrossRefPubMed

11.

Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet. 2007;40:17. https://doi.org/10.1038/ng.2007.53.CrossRef

12.

Ahmed M, Lalloo F, Evans DG. Update on genetic predisposition to breast cancer. Expert Rev Anticancer Ther. 2009;9(8):1103–13. https://doi.org/10.1586/era.09.38.CrossRefPubMed

13.

Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. Am J Hum Genet. 2003;72(5):1117–30. https://doi.org/10.1086/375033.CrossRefPubMedPubMedCentral

14.

Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci U S A. 2014;111(39):14205–10. https://doi.org/10.1073/pnas.1415979111.CrossRefPubMedPubMedCentral

15.

Han X, Jemal A. Recent Patterns in Genetic Testing for Breast and Ovarian Cancer Risk in the U.S. Am J Prev Med. 2017;53(4):504–7. https://doi.org/10.1016/j.amepre.2017.04.014.CrossRefPubMed

16.

Vergote I, Banerjee S, Gerdes A-M, van Asperen C, Marth C, Vaz F, et al. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. Eur J Cancer. 2016;69:127–34. https://doi.org/10.1016/j.ejca.2016.10.006.CrossRefPubMed

17.

Anglian Breast Cancer Study G. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer. 2000;83(10):1301–8. https://doi.org/10.1054/bjoc.2000.1407.CrossRef

18.

Risch HA, McLaughlin JR, Cole DEC, Rosen B, Bradley L, Fan I, et al. Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin–Cohort Study in Ontario, Canada. J Natl Cancer Inst. 2006;98(23):1694–706. https://doi.org/10.1093/jnci/djj465.CrossRefPubMed

19.

Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68(3):700–10. https://doi.org/10.1086/318787.CrossRefPubMedPubMedCentral

20.

Hirsh-Yechezkel G, Chetrit A, Lubin F, Friedman E, Peretz T, Gershoni R, et al. Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in israel. Gynecol Oncol. 2003;89(3):494–8. https://doi.org/10.1016/S0090-8258(03)00152-5.CrossRefPubMed

21.

Derks-Smeets IAP, van Tilborg TC, van Montfoort A, Smits L, Torrance HL, Meijer-Hoogeveen M, et al. BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGD. J Assist Reprod Genet. 2017;34(11):1475–82. https://doi.org/10.1007/s10815-017-1014-3.CrossRefPubMedPubMedCentral

22.

Lambertini M, Goldrat O, Toss A, Azim HA Jr, Peccatori FA, Ignatiadis M, et al. Fertility and pregnancy issues in BRCA-mutated breast cancer patients. Cancer Treat Rev. 2017;59:61–70. https://doi.org/10.1016/j.ctrv.2017.07.001.CrossRefPubMed

23.

Rzepka-Górska I, Tarnowski B, Chudecka-Głaz A, Górski B, Zielińska D, Tołoczko-Grabarek A. Premature Menopause in Patients with BRCA1 Gene Mutation. Breast Cancer Res Treat. 2006;100(1):59–63. https://doi.org/10.1007/s10549-006-9220-1.CrossRefPubMed

24.

Finch A, Valentini A, Greenblatt E, Lynch HT, Ghadirian P, Armel S, et al. Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertil Steril. 2013;99(6):1724–8. https://doi.org/10.1016/j.fertnstert.2013.01.109.CrossRefPubMed

25.

Oktay K, Kim JY, Barad D, Babayev SN. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol. 2010;28(2):240–4. https://doi.org/10.1200/JCO.2009.24.2057.CrossRefPubMed

26.

Titus S, Li F, Stobezki R, Akula K, Unsal E, Jeong K, et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med. 2013;5(172):172ra21. https://doi.org/10.1126/scitranslmed.3004925.CrossRefPubMedPubMedCentral

27.

Lambertini M, Goldrat O, Ferreira AR, Dechene J, Azim HA Jr, Desir J, et al. Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients. Ann Oncol. 2017;29(1):237–43. https://doi.org/10.1093/annonc/mdx639.CrossRef

28.

Giordano S, Garrett-Mayer E, Mittal N, Smith K, Shulman L, Passaglia C, et al. Association of BRCA1 Mutations with Impaired Ovarian Reserve: Connection Between Infertility and Breast/Ovarian Cancer Risk. J Adolesc Young Adult Oncol. 2016;5(4):337–43. https://doi.org/10.1089/jayao.2016.0009.CrossRefPubMedPubMedCentral

29.

Phillips K-A, for the Kathleen Cuningham Consortium for Research into Familial Breast C, Collins IM, for the Kathleen Cuningham Consortium for Research into Familial Breast C, Milne RL, for the Kathleen Cuningham Consortium for Research into Familial Breast C, et al. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. Hum Reprod. 2016;31(5):1126–32. https://doi.org/10.1093/humrep/dew044.CrossRefPubMedPubMedCentral

30.

Wang ET, Pisarska MD, Bresee C, Ida Chen Y-D, Lester J, Afshar Y, et al. BRCA1 germline mutations may be associated with reduced ovarian reserve. Fertil Steril. 2014;102(6):1723–8. https://doi.org/10.1016/j.fertnstert.2014.08.014.CrossRefPubMedPubMedCentral

31.

Son K-A, Lee D-Y, Choi D. Association of BRCA Mutations and Anti-müllerian Hormone Level in Young Breast Cancer Patients. Front Endocrinol. 2019;10:235. https://doi.org/10.3389/fendo.2019.00235.CrossRef

32.

Broer SL, Broekmans FJM, Laven JSE, Fauser BCJM. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update. 2014;20(5):688–701. https://doi.org/10.1093/humupd/dmu020.CrossRefPubMed

33.

de la Noval BD. Potential implications on female fertility and reproductive lifespan in BRCA germline mutation women. Arch Gynecol Obstet. 2016;294(5):1099–103. https://doi.org/10.1007/s00404-016-4187-6.CrossRefPubMed

34.

Valentini A, Finch A, Lubinski J, Byrski T, Ghadirian P, Kim-Sing C, et al. Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2013;31(31):3914–9.CrossRefPubMedPubMedCentral

35.

Lambertini M, Goldrat O, Toss A, Azim HA, Peccatori FA, Ignatiadis M, et al. Fertility and pregnancy issues in BRCA-mutated breast cancer patients. Cancer Treat Rev. 2017;59:61–70. https://doi.org/10.1016/j.ctrv.2017.07.001.CrossRefPubMed

36.

Shapira M, Raanani H, Meirow D. IVF for fertility preservation in breast cancer patients--efficacy and safety issues. J Assist Reprod Genet. 2015;32(8):1171–8. https://doi.org/10.1007/s10815-015-0519-x.CrossRefPubMedPubMedCentral

37.

Bu R, Siraj AK, Al-Obaisi KAS, Beg S, Al Hazmi M, Ajarim D, et al. Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis. Int J Cancer. 2016;139(5):1091–7. https://doi.org/10.1002/ijc.30143.CrossRefPubMedPubMedCentral

38.

M. CostaConxi LazaroLidia FeliubadalóBegoña GrañaIgnacio BlancoMiguel de la HoyaTrinidad CaldésPhilippe MailletGaelle Benais-PontBruno PardoYael LaitmanEitan FriedmanEladio A. VelascoMercedes DuránMaria-Dolores MiramarAna Rodriguez ValleMaría-Teresa CalvoAna VegaAna BlancoOrland DiezSara Gutiérrez-EnríquezJudith BalmañaTeresa Ramon y CajalCarmen AlonsoMontserrat BaigetWilliam FoulkesMarc TischkowitzRachel KyleNelly SabbaghianPatricia Ashton-ProllaIngrid P. EwaldThangarajan RajkumarLuisa Mota-VieiraGiuseppe GianniniAlberto GulinoMaria I. AchatzDirce M. CarraroBrigitte Bressac de PailleretsAudrey RemenierasCindy BensonSilvia CasadeiMary-Claire KingErik TeugelsManuel R. Teixeira APSPPJSRGAvdH-MGTAKCS-JBUCRLYPNR. International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. Breast Cancer Res Treat. 2011;127(3):671–9.CrossRef

39.

Peixoto A, Salgueiro N, Santos C, Varzim G, Rocha P, Soares MJ, et al. BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families. Familial Cancer. 2006;5(4):379–87.CrossRefPubMed

40.

Kwong A, Ng EKO, Wong CLP, Law FBF, Au T, Wong HN, et al. Identification of BRCA1/2 Founder Mutations in Southern Chinese Breast Cancer Patients Using Gene Sequencing and High Resolution DNA Melting Analysis. PLoS One. 2012;7(9):e43994. https://doi.org/10.1371/journal.pone.0043994.CrossRefPubMedPubMedCentral

41.

Kwong A, Wong LP, Wong HN, Law FBF, Ng EKO, Tang YH, et al. A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer. Breast Cancer Res Treat. 2009;117(3):683–6. https://doi.org/10.1007/s10549-009-0385-2.CrossRefPubMed

42.

Cao W-M, Gao Y, Yang H-J, Xie S-N, Ding X-W, Pan Z-W, et al. Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer. BMC Cancer. 2016;16(1):64. https://doi.org/10.1186/s12885-016-2107-6.CrossRefPubMedPubMedCentral

43.

Li W-F, Hu Z, Rao N-Y, Song C-G, Zhang B, Cao M-Z, et al. The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat. 2008;110(1):99–109. https://doi.org/10.1007/s10549-007-9708-3.CrossRefPubMed

44.

Fang M, Zhu L, Li H, Li X, Wu Y, Wu K, et al. Characterization of mutations in BRCA1/2 and the relationship with clinic-pathological features of breast cancer in a hereditarily high-risk sample of chinese population. Oncol Lett. 2017;15. https://doi.org/10.3892/ol.2017.7717.

45.

Shi T, Wang P, Xie C, Yin S, Shi D, Wei C, et al. BRCA1 and BRCA2 mutations in ovarian cancer patients from China: Ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer. Int J Cancer. 2017;140. https://doi.org/10.1002/ijc.30633.CrossRefPubMed

46.

Palma MD, Domchek SM, Stopfer J, Erlichman J, Siegfried JD, Tigges-Cardwell J, et al. The Relative Contribution of Point Mutations and Genomic Rearrangements in BRCA1 and BRCA2 in High-Risk Breast Cancer Families. Cancer Res. 2008;68(17):7006–14. https://doi.org/10.1158/0008-5472.Can-08-0599.CrossRefPubMedPubMedCentral

47.

Pujadelauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–84.CrossRef

48.

Hansen AR, Bedard PL. Clinical application of high-throughput genomic technologies for treatment selection in breast cancer. Breast Cancer Res. 2013;15(5):1–10.CrossRef

49.

Laurent C, Sophie K, Antoine R, Angélina L, Jean-Jacques B, Olivia B, et al. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. Eur J Hum Genet. 2014;22(11):1305–13.CrossRef

50.

Ellison G, Wallace A, Kohlmann A, Patton S. A comparative study of germline BRCA1 and BRCA2 mutation screening methods in use in 20 European clinical diagnostic laboratories. Br J Cancer. 2017;117(5):710–6. https://doi.org/10.1038/bjc.2017.223.CrossRefPubMedPubMedCentral

51.

Drohan B, Roche CA, Cusack JC, Hughes KS. Hereditary Breast and Ovarian Cancer and Other Hereditary Syndromes: Using Technology to Identify Carriers. Ann Surg Oncol. 2012;19(6):1732–7. https://doi.org/10.1245/s10434-012-2257-y.CrossRefPubMed

52.

Hampel H, Sweet K, Westman JA, Offit K, Eng C. Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J Med Genet. 2004;41(2):81. https://doi.org/10.1136/jmg.2003.010918.CrossRefPubMedPubMedCentral

53.

Bellcross C, Hermstad A, Tallo C, Stanislaw C. Validation of Version 3.0 of the Breast Cancer Genetics Referral Screening Tool (B-RST™). Genet Med. 2019;21(1):181–4. https://doi.org/10.1038/s41436-018-0020-x.CrossRefPubMed

54.

Bellcross CA, Lemke AA, Pape LS, Tess AL, Meisner LT. Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population. Genet Med. 2009;11:783. https://doi.org/10.1097/GIM.0b013e3181b9b04a.CrossRefPubMed

55.

Ovarian tissue cryopreservation: a committee opinion. Fertil Steril. 2014;101(5):1237–43. https://doi.org/10.1016/j.fertnstert.2014.02.052.

56.

Arslan M, Bocca S, Mirkin S, Barroso G, Stadtmauer L, Oehninger S. Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr. Fertil Steril. 2005;84(3):555–69. https://doi.org/10.1016/j.fertnstert.2005.02.053.CrossRefPubMed

57.

Bedoschi G, Oktay K. Current approach to fertility preservation by embryo cryopreservation. Fertil Steril. 2013;99(6):1496–502. https://doi.org/10.1016/j.fertnstert.2013.03.020.CrossRefPubMedPubMedCentral

58.

Vuković P, Kasum M, Raguž J, Lonjak N, Bilić Knežević S, Orešković I, et al. Fertility preservation in young women with early-stage breast cancer. Acta Clin Croat. 2019;58(1):147–56. https://doi.org/10.20471/acc.2019.58.01.19.CrossRefPubMedPubMedCentral

59.

Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril. 2013;100(6):1673–80. https://doi.org/10.1016/j.fertnstert.2013.07.1992.CrossRefPubMed

60.

Nakasuji T, Kawai K, Ishikawa T, Teraoka K, Takeuchi S, Miyagawa T, et al. Random-start ovarian stimulation with aromatase inhibitor for fertility preservation in women with Japanese breast cancer. Reprod Med Biol. 2019;18(2):167–72. https://doi.org/10.1002/rmb2.12263.CrossRefPubMedPubMedCentral

61.

Larman MG, Minasi MG, Rienzi L, Gardner DK. Maintenance of the meiotic spindle during vitrification in human and mouse oocytes. Reprod BioMed Online. 2007;15(6):692–700.CrossRefPubMed

62.

Luciano AM, Chigioni S, Lodde V, Franciosi F, Luvoni GC, Modina SC. Effect of different cryopreservation protocols on cytoskeleton and gap junction mediated communication integrity in feline germinal vesicle stage oocytes. Cryobiology. 2009;59(1):90–5.CrossRefPubMed

63.

Gomes C, Merlini M, Konheim J, Serafini P, Motta EL, Baracat EC, et al. Oocyte meiotic-stage-specific differences in spindle depolymerization in response to temperature changes monitored with polarized field microscopy and immunocytochemistry. Fertil Steril. 2012;97(3):714–9.CrossRefPubMed

64.

Silber S. Ovarian tissue cryopreservation and transplantation: scientific implications. J Assist Reprod Genet. 2016;33(12):1595–603. https://doi.org/10.1007/s10815-016-0814-1.CrossRefPubMedPubMedCentral

65.

Donnez J, Dolmans M-M. Fertility Preservation in Women. N Engl J Med. 2017;377(17):1657–65. https://doi.org/10.1056/NEJMra1614676.CrossRefPubMed

66.

Donnez J, Dolmans M-M. Ovarian cortex transplantation: 60 reported live births brings the success and worldwide expansion of the technique towards routine clinical practice. J Assist Reprod Genet. 2015;32(8):1167–70. https://doi.org/10.1007/s10815-015-0544-9.CrossRefPubMedPubMedCentral

67.

Hoekman EJ, Louwe LA, Rooijers M, van der Westerlaken LAJ, Klijn NF, Pilgram GSK et al. Ovarian tissue cryopreservation: low usage rates and high life birth rate after transplantation. Acta Obstetricia et Gynecologica Scandinavica.0(ja). 10.1111/aogs.13735.

68.

Rodriguez-Wallberg KA, Tanbo T, Tinkanen H, Thurin-Kjellberg A, Nedstrand E, Kitlinski ML, et al. Ovarian tissue cryopreservation and transplantation among alternatives for fertility preservation in the Nordic countries - compilation of 20 years of multicenter experience. Acta Obstet Gynecol Scand. 2016;95(9):1015–26.CrossRefPubMedPubMedCentral

69.

Imbert R, Moffa F, Tsepelidis S, Simon P, Delbaere A, Devreker F, et al. Safety and usefulness of cryopreservation of ovarian tissue to preserve fertility: a 12-year retrospective analysis. Hum Reprod. 2014;29(9):1931–40. https://doi.org/10.1093/humrep/deu158.CrossRefPubMed

70.

Suzuki N, Yoshioka N, Takae S, Sugishita Y, Tamura M, Hashimoto S, et al. Successful fertility preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency. Hum Reprod. 2015;30(3):608–15. https://doi.org/10.1093/humrep/deu353.CrossRefPubMed

71.

Shi Q, Xie Y, Wang Y, Li S. Vitrification versus slow freezing for human ovarian tissue cryopreservation: a systematic review and meta-anlaysis. Sci Rep. 2017;7(1):8538. https://doi.org/10.1038/s41598-017-09005-7.

72.

Abir R, Ben-Aharon I, Garor R, Yaniv I, Ash S, Stemmer SM, et al. Cryopreservation of in vitro matured oocytes in addition to ovarian tissue freezing for fertility preservation in paediatric female cancer patients before and after cancer therapy. Hum Reprod. 2016;31(4):750–62. https://doi.org/10.1093/humrep/dew007.CrossRefPubMed

73.

Kristensen SG, Giorgione V, Humaidan P, Alsbjerg B, Bjørn AB, Ernst E, et al. Fertility preservation and refreezing of transplanted ovarian tissue-a potential new way of managing patients with low risk of malignant cell recurrence. Fertil Steril. 2017;107(5):1206–13.CrossRefPubMed

74.

Jensen AK, Kristensen SG, Macklon KT, Jeppesen JV, Fedder J, Ernst E, et al. Outcomes of transplantations of cryopreserved ovarian tissue to 41 women in Denmark. Hum Reprod. 2015;30(12):2838–45. https://doi.org/10.1093/humrep/dev230.CrossRefPubMed

75.

Takae S, Suzuki N. Current state and future possibilities of ovarian tissue transplantation. Reprod Med Biol. 2019;18(3):217–24.CrossRefPubMedPubMedCentral

76.

Bastings L, Beerendonk CCM, Westphal JR, Massuger LFAG, Kaal SEJ, van Leeuwen FE, et al. Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review. Hum Reprod Update. 2013;19(5):483–506. https://doi.org/10.1093/humupd/dmt020.CrossRefPubMed

77.

Pacheco F, Oktay K. Current Success and Efficiency of Autologous Ovarian Transplantation: A Meta-Analysis. Reprod Sci. 2017;24(8):1111–20. https://doi.org/10.1177/1933719117702251.CrossRefPubMed

78.

Rosendahl M, Timmermans Wielenga V, Nedergaard L, Kristensen SG, Ernst E, Rasmussen PE, et al. Cryopreservation of ovarian tissue for fertility preservation: no evidence of malignant cell contamination in ovarian tissue from patients with breast cancer. Fertil Steril. 2011;95(6):2158–61. https://doi.org/10.1016/j.fertnstert.2010.12.019.CrossRefPubMed

79.

Vermeulen M, Giudice MG, Del Vento F, Wyns C. Role of stem cells in fertility preservation: current insights. Stem Cells Cloning. 2019;12(undefined):27–48.PubMedPubMedCentral

80.

Akahori T, Woods DC, Tilly JL. Female Fertility Preservation through Stem Cell-based Ovarian Tissue Reconstitution In Vitro and Ovarian Regeneration In Vivo. Clin Med insights Reprod Health. 2019;13(undefined):1179558119848007.PubMedPubMedCentral

81.

Arav A, Patrizio P. Techniques of Cryopreservation for Ovarian Tissue and Whole Ovary. Clin Med insights Reprod Health. 2019;13(undefined):1179558119884945.PubMedPubMedCentral

82.

Sheshpari S, Shahnazi M, Mobarak H, Ahmadian S, Bedate AM, Nariman-Saleh-Fam Z, et al. Ovarian function and reproductive outcome after ovarian tissue transplantation: a systematic review. J Transl Med. 2019;17(1):396.CrossRefPubMedPubMedCentral

83.

Sagi M, Weinberg N, Eilat A, Aizenman E, Werner M, Girsh E, et al. Preimplantation genetic diagnosis for BRCA1/2—a novel clinical experience. Prenat Diagn. 2009;29(5):508–13. https://doi.org/10.1002/pd.2232.CrossRefPubMed

84.

Paluch-Shimon S, Meirow D, Hyman J. Reproductive Issues in BRCA Mutation Carriers. In: Biglia N, Peccatori FA, editors. Breast Cancer, Fertility Preservation and Reproduction. Cham: Springer International Publishing; 2015. p. 83–102.CrossRef

85.

De Rycke M, Goossens V, Kokkali G, Meijer-Hoogeveen M, Coonen E, Moutou C. ESHRE PGD Consortium data collection XIV–XV: cycles from January 2011 to December 2012 with pregnancy follow-up to October 2013†. Hum Reprod. 2017;32(10):1974–94. https://doi.org/10.1093/humrep/dex265.CrossRefPubMed

86.

Wang Q, Chow JFC, Yeung WSB, Lau EYL, Lee VCY, Ng EHY, et al. Preimplantation genetic diagnosis using combined strategies on a breast cancer patient with a novel genomic deletion in BRCA2. J Assist Reprod Genet. 2014;31(12):1719–26. https://doi.org/10.1007/s10815-014-0355-4.CrossRefPubMedPubMedCentral

87.

Harton GL, De Rycke M, Fiorentino F, Moutou C, SenGupta S, Traeger-Synodinos J, et al. ESHRE PGD consortium best practice guidelines for amplification-based PGD†. Hum Reprod. 2010;26(1):33–40. https://doi.org/10.1093/humrep/deq231.CrossRefPubMed

88.

Richards L. The importance of early referral to fertility preservation. Nat Rev Clin Oncol. 2010;8:4. https://doi.org/10.1038/nrclinonc.2010.200.CrossRef

89.

Lee S, Ozkavukcu S, Heytens E, Moy F, Oktay K. Value of Early Referral to Fertility Preservation in Young Women With Breast Cancer. J Clin Oncol. 2010;28(31):4683–6. https://doi.org/10.1200/JCO.2010.30.5748.CrossRefPubMedPubMedCentral

90.

Eleje GU, Eke AC, Ezebialu IU, Ikechebelu JI, Ugwu EO, Okonkwo OO. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. Cochrane Database Syst Rev. 2018;8(undefined):CD012464.PubMed

91.

ACOG Practice Bulletin No. 103. Hereditary breast and ovarian cancer syndrome. Obstet Gynecol. 2009;113(4):957–66.CrossRef

92.

Peccatori FA, Mangili G, Bergamini A, Filippi F, Martinelli F, Ferrari F, et al. Fertility preservation in women harboring deleterious BRCA mutations: ready for prime time? Hum Reprod. 2017;33(2):181–7. https://doi.org/10.1093/humrep/dex356.CrossRef

93.

Kasum M, von Wolff M, Franulić D, Čehić E, Klepac-Pulanić T, Orešković S, et al. Fertility preservation options in breast cancer patients. Gynecol Endocrinol. 2015;31(11):846–51. https://doi.org/10.3109/09513590.2015.1081684.CrossRefPubMed

94.

Kotsopoulos J, Librach CL, Lubinski J, Gronwald J, Kim-Sing C, Ghadirian P, et al. Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case–control study. Cancer Causes Control. 2008;19(10):1111–9. https://doi.org/10.1007/s10552-008-9175-0.CrossRefPubMed

95.

Oktay K, Turan V, Bedoschi G, Pacheco FS, Moy F. Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer. J Clin Oncol. 2015;33(22):2424–9.CrossRefPubMedPubMedCentral

96.

Kim J-Y, Moon H-G, Kang Y-J, Han W, Noh W-C, Jung Y, et al. The Effect of Reproductive Factors on Breast Cancer Presentation in Women Who Are BRCA Mutation Carrier. J Breast Cancer. 2017;20(3):279–85.CrossRefPubMedPubMedCentral

97.

Blakely LJ, Buzdar AU, Lozada JA, Shullaih SA, Hoy E, Smith TL, et al. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer. 2004;100(3):465–9. https://doi.org/10.1002/cncr.11929.CrossRefPubMed

98.

Dabrosin C. An overview of pregnancy and fertility issues in breast cancer patients. Ann Med. 2015;47(8):673–8. https://doi.org/10.3109/07853890.2015.1096953.CrossRefPubMed

99.

Trefoux-Bourdet A, Reynaud-Bougnoux A, Body G, Ouldamer L. Grossesse après cancer du sein : revue de la littérature. Presse Med. 2019;48(4):376–83. https://doi.org/10.1016/j.lpm.2019.01.011.CrossRefPubMed

100.

Córdoba O, Bellet M, Vidal X, Cortés J, Llurba E, Rubio IT, et al. Pregnancy after treatment of breast cancer in young women does not adversely affect the prognosis. Breast. 2012;21(3):272–5. https://doi.org/10.1016/j.breast.2011.10.001.CrossRefPubMed

101.

Kotsopoulos J, Lubinski J, Salmena L, Lynch HT, Kim-Sing C, Foulkes WD, et al. Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2012;14(2):R42.CrossRefPubMedPubMedCentral

102.

Amant F, Berveiller P, Boere IA, Cardonick E, Fruscio R, Fumagalli M, et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. Ann Oncol. 2019;30(10):1601–12.CrossRefPubMed

103.

Stopenski S, Aslam A, Zhang X, Cardonick E. After Chemotherapy Treatment for Maternal Cancer During Pregnancy, Is Breastfeeding Possible? Breastfeed Med. 2017;12(undefined):91–7.CrossRefPubMed

104.

Leal SC, Stuart SR, Carvalho Hde A. Breast irradiation and lactation: a review. Expert Rev Anticancer Ther. 2013;13(2):159–64.CrossRefPubMed

105.

Shah NM, Scott DM, Kandagatla P, Moravek MB, Cobain EF, Burness ML, et al. Young Women with Breast Cancer: Fertility Preservation Options and Management of Pregnancy-Associated Breast Cancer. Ann Surg Oncol. 2019;26(5):1214–24.CrossRefPubMedPubMedCentral

106.

Marion D, Jos CD, Inge D-S, Edith C. Ron vG, Jannie vE-A et al. PGD for hereditary breast and ovarian cancer: the route to universal tests for BRCA1 and BRCA2 mutation carriers. Eur J Hum Genet Ejhg. 2013;21(12):1361–8.CrossRef

107.

Derks-Smeets IAP, Gietel-Habets JJG, Tibben A, Tjan-Heijnen VCG, Meijer-Hoogeveen M, Geraedts JPM, et al. Decision-making on preimplantation genetic diagnosis and prenatal diagnosis: a challenge for couples with hereditary breast and ovarian cancer. Hum Reprod. 2014;29(5):1103–12. https://doi.org/10.1093/humrep/deu034.CrossRefPubMed

108.

Hoskins LM, Allison WL. A multi-case report of the pathways to and through genetic testing and cancer risk management for BRCA mutation-positive women aged 18-25. J Genet Couns. 2013;22(1):27–38.CrossRefPubMed

109.

Gietel-Habets JJG, de Die-Smulders CEM, Derks-Smeets IAP, Tibben A, Tjan-Heijnen VCG, van Golde R, et al. Awareness and attitude regarding reproductive options of persons carrying a BRCA mutation and their partners. Hum Reprod. 2017;32(3):588–97. https://doi.org/10.1093/humrep/dew352.CrossRefPubMed

110.

Mai PL, Piedmonte M, Han PK, Moser RP, Walker JL, Rodriguez G, et al. Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017;145(1):122–9. https://doi.org/10.1016/j.ygyno.2017.02.008.CrossRefPubMedPubMedCentral

111.

Goetsch AL, Wicklund C, Clayman ML, Woodruff TK. Reproductive Endocrinologists’ Utilization of Genetic Counselors for Oncofertility and Preimplantation Genetic Diagnosis (PGD) Treatment of BRCA1/2 Mutation Carriers. J Genet Couns. 2016;25(3):561–71.CrossRefPubMed

112.

Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018;36(19):1994–2001. https://doi.org/10.1200/JCO.2018.78.1914.CrossRefPubMed

113.

Azim AA, Maria CF, Lostritto K, ., Kutluk O. Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab 2007;92(6):2197-2200.CrossRefPubMed

114.

Domingo J, Garciavelasco JA. Oocyte cryopreservation for fertility preservation in women with cancer. Cur Opi Endocrinol Diab Obes. 2016;23(6):465.CrossRef

Title: Fertility preservation in BRCA mutation carriers—efficacy and safety issues: a review
Authors: Xiaofu Zhang
Jingxin Niu
Tuanjie Che
Yibei Zhu
Hongtao Zhang
Jing Qu
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Fertility
Breast Cancer
Breast Cancer
Published in: Reproductive Biology and Endocrinology / Issue 1/2020
Electronic ISSN: 1477-7827
DOI: https://doi.org/10.1186/s12958-019-0561-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Fertility preservation in BRCA mutation carriers—efficacy and safety issues: a review

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

The best execution of the DuoStim strategy (double stimulation in the follicular and luteal phase of the same ovarian cycle) in patients who are poor ovarian responders

Early maternal separation accelerates the progression of endometriosis in adult mice

Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study

Advanced paternal age: effects on sperm parameters, assisted reproduction outcomes and offspring health

Correlation of low serum vitamin-D with uterine leiomyoma: a systematic review and meta-analysis

Non-esterified fatty acids in the ovary: friends or foes?